FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2138838585> ?p ?o ?g. }

• W2138838585 endingPage "68" @default.
• W2138838585 startingPage "3658" @default.
• W2138838585 abstract "Patients with multiple myeloma (MM) invariably relapse with chemotherapy-resistant disease, underscoring the need for new agents that bypass these resistance mechanisms. We have reported that ascorbic acid (AA) enhances the activity of arsenic trioxide (As(2)0(3)) against drug-resistant MM in vitro by depleting intracellular glutathione (GSH). These data led us to open a National Cancer Institute/Cancer Therapy Evaluation Program-sponsored Phase I/II trial of As(2)0(3) + AA for relapsed/refractory MM. We now present the completed Phase I component of this trial. The primary objective of the trial's Phase I component was to assess whether the addition of AA affected the well-described toxicity profile of As(2)0(3) alone. Correlative studies were undertaken of As(2)0(3) and AA pharmacokinetics, the ability of AA to deplete intracellular GSH in vivo, and the development of arsenic resistance. Six patients with stage IIIA relapsed/refractory myeloma were studied. We found that 0.25 mg/kg/day As(2)O(3) + 1,000 mg/day AA could be given for 25 days (over a 35-day period) without dose-limiting toxicity. One episode of grade 3 hematological toxicity (leukopenia) and no grade 3 nonhematological toxicities (in particular, cardiac) were observed. The coadministration of AA did not alter the pharmacokinetics of As(2)0(3), and elevated AA levels were associated with decreased intracellular GSH. Serial in vitro studies demonstrated continued sensitivity of patient myeloma cells to As(2)0(3) + AA. Two patients (both with thalidomide-refractory disease) had partial responses; four patients had stable disease. In conclusion, we have found that As(2)0(3) + AA has acceptable toxicity and that there is promising evidence of activity in refractory/relapsed myeloma." @default.
• W2138838585 created "2016-06-24" @default.
• W2138838585 creator A5012866839 @default.
• W2138838585 creator A5017327825 @default.
• W2138838585 creator A5035390592 @default.
• W2138838585 creator A5037735219 @default.
• W2138838585 creator A5037909608 @default.
• W2138838585 creator A5043268265 @default.
• W2138838585 creator A5046430988 @default.
• W2138838585 creator A5050227848 @default.
• W2138838585 creator A5052699590 @default.
• W2138838585 creator A5056936589 @default.
• W2138838585 creator A5065238694 @default.
• W2138838585 date "2002-12-01" @default.
• W2138838585 modified "2023-09-28" @default.
• W2138838585 title "Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma." @default.
• W2138838585 cites W11654018 @default.
• W2138838585 cites W134636856 @default.
• W2138838585 cites W1528751727 @default.
• W2138838585 cites W1559603064 @default.
• W2138838585 cites W1587537557 @default.
• W2138838585 cites W1692919389 @default.
• W2138838585 cites W1754065147 @default.
• W2138838585 cites W1857262284 @default.
• W2138838585 cites W1931891535 @default.
• W2138838585 cites W1942619170 @default.
• W2138838585 cites W1953775887 @default.
• W2138838585 cites W1982330330 @default.
• W2138838585 cites W2023148609 @default.
• W2138838585 cites W2031832448 @default.
• W2138838585 cites W2036084283 @default.
• W2138838585 cites W2038933446 @default.
• W2138838585 cites W2049457454 @default.
• W2138838585 cites W2062837765 @default.
• W2138838585 cites W2064931441 @default.
• W2138838585 cites W2072103198 @default.
• W2138838585 cites W2079177599 @default.
• W2138838585 cites W2080468905 @default.
• W2138838585 cites W2085766228 @default.
• W2138838585 cites W2086564382 @default.
• W2138838585 cites W2088104197 @default.
• W2138838585 cites W2088489718 @default.
• W2138838585 cites W2095357364 @default.
• W2138838585 cites W2096971694 @default.
• W2138838585 cites W2101699988 @default.
• W2138838585 cites W2106170234 @default.
• W2138838585 cites W2119994407 @default.
• W2138838585 cites W2142423276 @default.
• W2138838585 cites W2150293665 @default.
• W2138838585 cites W2169842737 @default.
• W2138838585 cites W2174990671 @default.
• W2138838585 cites W2260584921 @default.
• W2138838585 cites W2314037093 @default.
• W2138838585 cites W2316160054 @default.
• W2138838585 cites W2318467720 @default.
• W2138838585 cites W2413386150 @default.
• W2138838585 cites W7064723 @default.
• W2138838585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12473574" @default.
• W2138838585 hasPublicationYear "2002" @default.
• W2138838585 type Work @default.
• W2138838585 sameAs 2138838585 @default.
• W2138838585 citedByCount "54" @default.
• W2138838585 countsByYear W21388385852012 @default.
• W2138838585 countsByYear W21388385852013 @default.
• W2138838585 countsByYear W21388385852014 @default.
• W2138838585 countsByYear W21388385852015 @default.
• W2138838585 countsByYear W21388385852016 @default.
• W2138838585 countsByYear W21388385852017 @default.
• W2138838585 countsByYear W21388385852018 @default.
• W2138838585 countsByYear W21388385852020 @default.
• W2138838585 countsByYear W21388385852021 @default.
• W2138838585 countsByYear W21388385852022 @default.
• W2138838585 crossrefType "journal-article" @default.
• W2138838585 hasAuthorship W2138838585A5012866839 @default.
• W2138838585 hasAuthorship W2138838585A5017327825 @default.
• W2138838585 hasAuthorship W2138838585A5035390592 @default.
• W2138838585 hasAuthorship W2138838585A5037735219 @default.
• W2138838585 hasAuthorship W2138838585A5037909608 @default.
• W2138838585 hasAuthorship W2138838585A5043268265 @default.
• W2138838585 hasAuthorship W2138838585A5046430988 @default.
• W2138838585 hasAuthorship W2138838585A5050227848 @default.
• W2138838585 hasAuthorship W2138838585A5052699590 @default.
• W2138838585 hasAuthorship W2138838585A5056936589 @default.
• W2138838585 hasAuthorship W2138838585A5065238694 @default.
• W2138838585 hasConcept C112705442 @default.
• W2138838585 hasConcept C126322002 @default.
• W2138838585 hasConcept C142424586 @default.
• W2138838585 hasConcept C181199279 @default.
• W2138838585 hasConcept C185592680 @default.
• W2138838585 hasConcept C2776694085 @default.
• W2138838585 hasConcept C29730261 @default.
• W2138838585 hasConcept C2986274086 @default.
• W2138838585 hasConcept C31903555 @default.
• W2138838585 hasConcept C538909803 @default.
• W2138838585 hasConcept C55493867 @default.
• W2138838585 hasConcept C71924100 @default.
• W2138838585 hasConcept C86803240 @default.
• W2138838585 hasConcept C87355193 @default.

• next